Abstract
Phenylacetate, a common metabolite of phenylalanine, is a natural component of the human plasma and an endogenous growth regulator in plants (1,2). In humans, phenylacetate conjugates glutamine to yield phenylacetylglutamine (PAG), which is subsequently excreted in the urine. The latter, leading to waste nitrogen excretion, has been the basis for using sodium phenylacetate (NaPA) in treatment of hyperammonemia associated with inborn errors of urea synthesis or liver failure (3,4). Clinical experience obtained with these patients indicated that long-term treatment with high doses of NaPA (250–550 mg/kg/day) is well tolerated by both infants and adults, and effective in reducing plasma glutamine levels. These characteristics should be of value in cancer intervention considering the unique dependence of tumor cells on circulating glutamine. Preclinical studies exploring the antitumor efficacy of NaPA revealed that this simple aromatic fatty acid can selectively suppress the growth of various tumors in tissue culture and in animal models (5–7; Samid et al, unpublished). In addition to glutamine depletion in humans, phenylacetate was found to induce tumor cytostasis and differentiation through several other mechanisms (see below). Most importantly, the antitumor activity was observed with pharmacological, non-toxic drug concentrations. The demonstrated antitumor activity, easy administration (oral or IV), and lack of significant adverse effects, made phenylacetate an attractive candidate for clinical use in prevention and treatment of human neoplasms, including those which do not respond to conventional therapies. In the present report we provide a brief summary of the preclinical antitumor activity of NaPA and its derivatives.
Keywords
- Urea Synthesis
- Solid Tumor Cell Line
- Endogenous Growth Regulator
- Sodium Phenylbutyrate
- Demonstrate Antitumor Activity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Sandler, M., Ruthven, C.R.J., Goodwin, B.L. Lee, A. and Stern, G.M. J. Neurol. Neurosurg. Psych. 45:366–368, 1982.
Wightman, F. and Lighty, D.L. Physiol. Plant. 55:17–24, 1982.
Brusilow, S.W., Danney, M., Waber, L.J., Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeethren, C. and Ward, J. N. Eng. J. Med. 310:1630–1634, 1984.
Simell, O., Sipila, L, Rajantie, J., Valle, D.L. and Brusilow, S.W. Pediatric Res. 20:1117–1121, 1986.
Samid D., Shack, S. and Sherman, L.T. Cancer Res. 52:1988–1992, 1992.
Samid D., Yeh, A. and Prasanna, P. Blood 80:1576–1581, 1992
Samid, D., Shack, S. and Myers, CE. J. Clin. Invest. 91:2288–2295, 1993.
Cinatl, J. et al. 70:15-24, 1993.
Gorski G.K., McMorrow L.E. and Donaldson M.H. In Vitro Cel. Dev. Biol. 29A: 189–191, 1993.
Muir, R.M., Fujita, T. and Hansch, C. Plant Physiol. 42:1519–1526, 1967.
Vanjusin, B.F., Bashkite, E.A., Friedrich, A. and Chvojka, L. Biochemia 1, 46:47–53, 1981.
Fibach, E., Prasanna, P., Rodgers, G.P. and Samid, D. Blood 82:2203–2209, 1993.
Dover, G.J., Brusilow, S. and Samid, D. New Engl J Med 327:569–570, 1992
Nebert, D.W. Nature 347:709–710, 1990.
Goldstein, J.L. and Brown, M.S. Nature 343:425–430, 1990.
Marshall, C.J. Science 259:1865–1866, 1993.
Castillo, M. Iglesias, J., Zafra, M.F. and Garcia-Peregrin, E. Neurochem. Int. 18:171–174, 1991.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Samid, D., Hudgins, W.R., Shack, S., Liu, L., Prasanna, P., Myers, C.E. (1997). Phenylacetate and Phenylbutyrate as Novel, Nontoxic Differentiation Inducers. In: Honn, K.V., Nigam, S., Marnett, L.J. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2. Advances in Experimental Medicine and Biology, vol 400. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5325-0_67
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5325-0_67
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7430-5
Online ISBN: 978-1-4615-5325-0
eBook Packages: Springer Book Archive